A PCR-based microwell-plate hybrid capture assay for high-risk human papillomavirus

Wang, Yumei; Liu, Yan; Ding, Yaping; Sun, Nan; Gong, Yuezheng; Gao, Shangxian

doi:10.1007/s00705-014-2186-0

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, there has been an increase in the detection methods for quantification of nucleic acids (Datta et al 2014;Wang et al 2014b), especially the use of real-time PCR assays (Cai et al 2014;dos Santos Ade et al 2014;Wang et al 2014a) that provide an easy and reliable routine for clinical laboratory tests. Possessing an outstanding quality control or standard is important to ensure precise results and to exclude inaccurate outcomes.…”

Section: Introductionmentioning

confidence: 99%

A novel method to produce armored double-stranded DNA by encapsulation of MS2 viral capsids

Zhang

Sun

Chang

et al. 2015

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

With the rapid development of molecular diagnostic techniques, there is a growing need for quality controls and standards with favorable properties to monitor the entire detection process. In this study, we describe a novel method to produce armored hepatitis B virus (HBV) and human papillomavirus (HPV) DNA for use in nucleic acid tests, which was confirmed to be stable, homogeneous, noninfectious, nuclease resistant, and safe for shipping. We demonstrated that MS2 bacteriophage could successfully package double-stranded DNA of 1.3-, 3-, 3.5-, and 6.5-kb length into viral capsids with high reassembly efficiency. This is the first application of RNA bacteriophage MS2 as a platform to encapsulate double-stranded DNA, forming virus-like particles (VLPs) which were indistinguishable from native MS2 capsids in size and morphology. Moreover, by analyzing the interaction mechanism of pac site and the MS2 coat protein (CP), we found that in addition to the recognized initiation signal TR-RNA, TR-DNA can also trigger spontaneous reassembly of CP dimers, providing a more convenient and feasible method of assembly. In conclusion, this straightforward and reliable manufacturing approach makes armored DNA an ideal control and standard for use in clinical laboratory tests and diagnostics, possessing prospects for broad application, especially providing a new platform for the production of quality controls for DNA viruses.

show abstract

Section: Introductionmentioning

confidence: 99%

A novel method to produce armored double-stranded DNA by encapsulation of MS2 viral capsids

Zhang

Sun

Chang

et al. 2015

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

On-nylon membrane detection of nucleic acid molecules by rolling circle amplification

Zhang

Gan

et al. 2017

Analytical Biochemistry

View full text Add to dashboard Cite

Molecular markers for cervical cancer screening

Güzel

Hoff

Kok

et al. 2021

Expert Review of Proteomics

View full text Add to dashboard Cite

This review gives an overview of current screening practices for cervical cancer. In the introduction, we will cover approaches of population screening focusing on high-risk Human Papilloma Virus (hrHPV) and the need for a better triage assay. We will further assess the impact of current vaccination programs on screening. Subsequently, the review will cover various technological aspects of nucleic acid-and protein-based biomarker assays. We will then detail different molecular markers in view of their use in triage assays, emphasizing epigenetic and protein markers. Finally, we will place this in the context of cost-effectiveness considerations in view of their implementation in high-as well as in low-to middle-income countries. Introduction: Cervical cancer remains a significant healthcare problem, notably in low-to middle-income countries. While a negative test for hrHPV has a predictive value of more than 99.5%, its positive predictive value is less than 10% for CIN2+ stages. This makes the use of a so-called triage test indispensable for population-based screening to avoid referring women, that are ultimately at low risk of developing cervical cancer, to a gynecologist. This review will give an overview of tests that are based on epigenetic marker panels and protein markers. Areas covered: There is a medical need for molecular markers with a better predictive value to discriminate hrHPV-positive women that are at risk of developing cervical cancer from those that are not. Areas covered are epigenetic and protein markers as well as health economic considerations in view of the fact that most cases of cervical cancer arise in low-to-middle-income countries. Expert opinion: While there are biomarker assays based on changes at the nucleic acid (DNA methylation patterns, miRNAs) and at the protein level, they are not widely used in population screening. Combining nucleic acid-based and protein-based tests could improve the overall specificity for discriminating CIN2+ lesions that carry a low risk of progressing to cervical cancer within the screening interval from those that carry an elevated risk. The challenge is to reduce unnecessary referrals without an undesired increase in false-negative diagnoses resulting in cases of cervical cancer that could have been prevented. A further challenge is to develop tests for low-and middle-income countries, which is critical to reduce the worldwide burden of cervical cancer.

show abstract

A PCR-based microwell-plate hybrid capture assay for high-risk human papillomavirus

Cited by 3 publications

References 22 publications

A novel method to produce armored double-stranded DNA by encapsulation of MS2 viral capsids

A novel method to produce armored double-stranded DNA by encapsulation of MS2 viral capsids

On-nylon membrane detection of nucleic acid molecules by rolling circle amplification

Molecular markers for cervical cancer screening

Contact Info

Product

Resources

About